Subscribe to RSS
DOI: 10.1055/s-0040-1718384
Beyond Expert Opinion: A Comparison of Antibiotic Regimens for Infectious Urinary Tract Pathology in Pregnancy
Abstract
Objective Outside pregnancy, nitrofurantoin, ciprofloxacin and sulfamethoxazole-trimethoprim (SMZ-TMP) are first-line therapy (FLT) for lower urinary tract infections (LUTIs). Optimal antibiotics for LUTI have been extrapolated based on expert opinion. Progression to pyelonephritis and adverse obstetric outcomes were compared between women who received FLT and those given alternative antibiotics.
Methods This study includes a retrospective cohort of women with LUTI, including asymptomatic bacteriuria and acute cystitis at single health care system from July 2013 to May 2019. Women receiving FLT, defined as nitrofurantoin or SMZ-TMP, were compared with those receiving nonfirst-line therapy (nFLT). Primary outcome was progression to pyelonephritis. Secondary outcomes included pyelonephritis-related anemia, sepsis, length of stay, preterm birth (PTB), and low birth weight (LBW). Logistic regression was used to calculate odds of outcomes.
Results Of 476 women, 336 (70.6%) received FLT and 140 (29.4%) received nFLT. Women receiving FLT were more likely having BMI ≥ 40 (p = 0.04). Progression to pyelonephritis did not differ (5.8 vs. 8.2%; p = 0.44), nor did other pyelonephritis-related outcomes. After controlling for confounders, no difference in odds of progression to pyelonephritis was seen (adjusted odds ratio [aOR] 1.02, 95% confidence interval [CI] 0.42, 2.49). FLT was not associated with PTB or LBW (aOR 0.60, 95% CI 0.29, 1.26) after controlling for confounders.
Conclusion Receipt of antibiotics other than nitrofurantoin or SMZ-TMP for LUTI in pregnancy was not associated with increased risk of progression to pyelonephritis, PTB, or LBW.
Keywords
asymptomatic bacteriuria - acute cystitis - nitrofurantoin - pyelonephritis - trimethoprim-sulfamethoxazole - uropathogen - urinary tract infectionsHighlights
• As per expert opinion, nitrofurantoin and sulfamethoxazole-trimethoprim (SMZ-TMP) are first line for lower urinary tract infections (LUTI) in pregnancy.
• Nonfirst-line drugs do not increase the rate of LUTI progression to pyelonephritis.
• Pyelonephritis and obstetric outcomes are similar regardless of antibiotic choice.
Financial Support
None to disclose.
Meeting Presentation Disclosure
This work was presented as a poster presentation at the Society for Maternal-Fetal Medicine's 40th Annual Pregnancy meeting in February 2019 in Dallas, Texas.
Condensation
Receipt of antibiotics other than nitrofurantoin or trimethoprim-sulfamethoxazole for LUTI in pregnancy is not associated with increased risk of progression to pyelonephritis.
Disclosure Statement
The authors report no conflict of interest.
Publication History
Received: 13 June 2020
Accepted: 20 July 2020
Article published online:
12 October 2020
© 2020. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Thieme Medical Publishers
333 Seventh Avenue, New York, NY 10001, USA.
